Microbiome & Chronic Diseases

Evidence Based Medicine
Sign in

Disease ⇒ Amyotrophic lateral sclerosis {40000171}

Record Keys

Amyotrophic lateral sclerosis
Parent:[  ]


Initialisation date:
Other Terms:


Meta Information

MedDra ID:
MedDra Level:
ICD:[  ]
Zone:[  ]
Mechanism:[  ]


Amyotrophic lateral sclerosis (ALS) is a rapidly progressive disease characterised by degeneration of the upper and lower motor neurons in the brain and spinal cord; this results in focal weakness, which later progresses to affect most muscles, including the diaphragm. The condition is fatal, with patients dying of respiratory failure after a mean progression time of 3-5 years.

References Notes

[  ]

Shared Reference Notes

  • [1.9
    - Nicotinamide produced by the Akkermansia muciniphila bacteria slowed disease progression and prolonged survival in an ALS mouse model. - Nicotinamide benefits may be linked with improvements in mitochondria function. - Nicotinamide and its intermediary molecules significantly reduced in ALS. - Nicotinamide levels were decreased in the brains of ALS patients; this reduction was associated with enhanced muscle weakness. - Ruminococcus torques and Parabacteroides distasonis worsened ALS symptoms (1)
  • [1.10
    - IL-8, IL-15, MCP-1 and VEGF-A levels were significantly lower in patients than controls, while others did not show a different distribution among groups. - IP-10 levels were positively correlated with survival.
  • [#Short Chain Fatty Acid] - The fecal SCFA concentrations (µmol/g) were not significantly different between ALS patients and controls, or between patients with different clinical characteristics.
  • [1.7
    - Greater abundance of #Ruminococcus, at genus level > related to higher risk of ALS. - #kynurenine > risk factor of ALS.
  • [1.12
    - In spinal motor neurons human induced pluripotent stem cell lines > elevated levels of #Arachidonic acid. - Pharmacological reduction of #Arachidonic acid levels > reverse ALS-related phenotypes in both human sMNs and in vivo in Drosophila and SOD1G93A mouse models.
  • [1.13
    - ALS in mice> altered bacterial community related to autoimmunity (e.g., #Clostridium sp. ASF502, #Lachnospiraceae bacterium A4), inflammation (e.g., #Enterohabdus Muris,), and metabolism (e.g., #Desulfovibrio fairfieldensis) at 1- and 2-month-old SOD1G93A mice, suggesting the early microbial contribution to the pathological changes.
  • [1.8
    - The gut microbial communities of the ALS patients were more diverse and were deficient in #Prevotella spp. compared with those of their spouses. - Predictive analysis of microbial enzymes revealed that ALS patients had decreased activity in several metabolic pathways, including carbon metabolism, #Butyrate metabolism, and systems involving histidine kinase and response regulators.
  • [1.4
    - ALS > greater abundance of Escherichia coli and Enterobacteria and lower abundance of yeasts and Clostridium in the patient group

Common References